A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas.

Trial Profile

A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2014

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Cancer; Neurofibromatoses
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2010 Actual end date changed from Mar 2010 to Nov 2010 as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Actual end date changed from Mar 2010 to Nov 2010 as reported by ClinicalTrials.gov.
    • 15 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top